Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The Allegro Phase 2b/3 Randomized Clinical Trial

October 2024 in “ American Journal of Clinical Dermatology ”

Rodney Sinclair, Natasha Atanaskova Mesinkovska, Debanjali Mitra, Dalia Wajsbrot, Ernest H. Law, Robert Wołk, Brett King

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

10 / 10 results

research Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata

23 citations , October 2024 in “British Journal of Dermatology”

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

research Patient-Reported Satisfaction With Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results From ALLEGRO-2b/3

2 citations , June 2024 in “Dermatology”

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Validation of the Alopecia Areata Patient Priority Outcomes Questionnaire in Adults and Adolescents with Alopecia Areata

22 citations , November 2021 in “Dermatology and Therapy”

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

research Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

67 citations , March 2021 in “Dermatology and Therapy”

Alopecia areata greatly harms quality of life, causing emotional and social issues.

research Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study

11 citations , March 2021 in “Dermatology and therapy”

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata

research ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata

30 citations , September 2020 in “Journal of Patient-Reported Outcomes”

Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.

research Epidemiology and Burden of Alopecia Areata: A Systematic Review

144 citations , July 2015 in “Clinical, Cosmetic and Investigational Dermatology”

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

162 citations , October 2014 in “Autoimmunity reviews”

Alopecia areata is caused by the immune system attacking hair follicles.

Related Research

3 / 3 results

Alopecia Areata: A Multifactorial Autoimmune Condition